FDA Approves New Neuropathy Pain Drug

To contact us Click HERE

Get ready for a trip to the emergencyroom if you take this drug inappropriately. Also, keep this drug outof reach of children of any age less than 18. These warnings arenecessary and very wise for a neuropathy pain drug just approved foruse by the FDA. 
Other warnings can be found here andneed to be taken seriously. For me, this will be one medication Iwill avoid if at all possible – FDA approval not withstanding. There are just too many potential risk hazards for me to becomfortable using this. The fact that this medication has to bedoctor monitored so closely because of potential of addiction isanother factor in my avoiding this medication.
The US Food and Drug Administrationhas approved US sales of NUCYNTA® ER (tapentadol), a twice-dailyextended-release oral analgesic for the treatment of pain fromdiabetic peripheral neuropathy. The drug, produced by NewJersey-based Janssen Pharmaceuticals, Inc., provides around-the-clockmanagement for moderate to severe chronic neuropathic pain. Janssensays that it is currently the only opioid on theUS market that has been approved for treating the condition.
I will continue to suffer with what Iconsiderate moderate chronic neuropathy pain rather that use thismedication. I will continue to use gabapentin, which alleviates someof the pain and is not a narcotic.
While this medication may work for somepeople, after reading the warnings accompanying the press release andthen the FDA link above, it is not a medication I wish to consider. This medication also has great potential for being abused like othercontrolled substances.